S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
Log in
NASDAQ:BIOL

BIOLASE Competitors

$0.91
-0.01 (-1.09 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.89
Now: $0.91
$0.99
50-Day Range
$0.48
MA: $1.05
$1.50
52-Week Range
$0.21
Now: $0.91
$1.51
Volume7.87 million shs
Average Volume45.48 million shs
Market Capitalization$132.43 million
P/E RatioN/A
Dividend YieldN/A
Beta1.98

Competitors

BIOLASE (NASDAQ:BIOL) Vs. UROV, CLVS, LABP, ALT, AMYT, and BDSX

Should you be buying BIOL stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to BIOLASE, including Urovant Sciences (UROV), Clovis Oncology (CLVS), Landos Biopharma (LABP), Altimmune (ALT), Amryt Pharma (AMYT), and Biodesix (BDSX).

BIOLASE (NASDAQ:BIOL) and Urovant Sciences (NASDAQ:UROV) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.

Risk and Volatility

BIOLASE has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500. Comparatively, Urovant Sciences has a beta of 2.36, suggesting that its stock price is 136% more volatile than the S&P 500.

Valuation and Earnings

This table compares BIOLASE and Urovant Sciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BIOLASE$37.80 million3.50$-17,850,000.00($0.77)-1.18
Urovant SciencesN/AN/A$-146,740,000.00($4.71)-3.43

BIOLASE has higher revenue and earnings than Urovant Sciences. Urovant Sciences is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BIOLASE and Urovant Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BIOLASE-58.34%-541.14%-45.22%
Urovant SciencesN/AN/A-162.90%

Institutional and Insider Ownership

5.5% of BIOLASE shares are owned by institutional investors. Comparatively, 18.4% of Urovant Sciences shares are owned by institutional investors. 2.2% of BIOLASE shares are owned by company insiders. Comparatively, 2.7% of Urovant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for BIOLASE and Urovant Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BIOLASE00103.00
Urovant Sciences03002.00

BIOLASE currently has a consensus price target of $2.00, indicating a potential upside of 120.46%. Urovant Sciences has a consensus price target of $16.1667, indicating a potential downside of 0.02%. Given BIOLASE's stronger consensus rating and higher possible upside, analysts clearly believe BIOLASE is more favorable than Urovant Sciences.

Summary

BIOLASE beats Urovant Sciences on 8 of the 13 factors compared between the two stocks.

BIOLASE (NASDAQ:BIOL) and Clovis Oncology (NASDAQ:CLVS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk.

Risk and Volatility

BIOLASE has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500. Comparatively, Clovis Oncology has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500.

Valuation and Earnings

This table compares BIOLASE and Clovis Oncology's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BIOLASE$37.80 million3.50$-17,850,000.00($0.77)-1.18
Clovis Oncology$143.01 million3.70$-400,420,000.00($7.60)-0.79

BIOLASE has higher earnings, but lower revenue than Clovis Oncology. BIOLASE is trading at a lower price-to-earnings ratio than Clovis Oncology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BIOLASE and Clovis Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BIOLASE-58.34%-541.14%-45.22%
Clovis Oncology-230.34%N/A-57.56%

Institutional & Insider Ownership

5.5% of BIOLASE shares are held by institutional investors. Comparatively, 57.8% of Clovis Oncology shares are held by institutional investors. 2.2% of BIOLASE shares are held by insiders. Comparatively, 6.6% of Clovis Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for BIOLASE and Clovis Oncology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BIOLASE00103.00
Clovis Oncology22202.00

BIOLASE currently has a consensus price target of $2.00, suggesting a potential upside of 120.46%. Clovis Oncology has a consensus price target of $8.80, suggesting a potential upside of 46.91%. Given BIOLASE's stronger consensus rating and higher probable upside, equities research analysts clearly believe BIOLASE is more favorable than Clovis Oncology.

Summary

Clovis Oncology beats BIOLASE on 8 of the 14 factors compared between the two stocks.

BIOLASE (NASDAQ:BIOL) and Landos Biopharma (NASDAQ:LABP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk.

Valuation and Earnings

This table compares BIOLASE and Landos Biopharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BIOLASE$37.80 million3.50$-17,850,000.00($0.77)-1.18
Landos BiopharmaN/AN/AN/AN/AN/A

Landos Biopharma has lower revenue, but higher earnings than BIOLASE.

Profitability

This table compares BIOLASE and Landos Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BIOLASE-58.34%-541.14%-45.22%
Landos BiopharmaN/AN/AN/A

Institutional & Insider Ownership

5.5% of BIOLASE shares are held by institutional investors. 2.2% of BIOLASE shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for BIOLASE and Landos Biopharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BIOLASE00103.00
Landos Biopharma0000N/A

BIOLASE currently has a consensus price target of $2.00, suggesting a potential upside of 120.46%. Given BIOLASE's higher probable upside, equities research analysts clearly believe BIOLASE is more favorable than Landos Biopharma.

Summary

BIOLASE beats Landos Biopharma on 5 of the 8 factors compared between the two stocks.

BIOLASE (NASDAQ:BIOL) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for BIOLASE and Altimmune, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BIOLASE00103.00
Altimmune00603.00

BIOLASE currently has a consensus price target of $2.00, suggesting a potential upside of 120.46%. Altimmune has a consensus price target of $31.75, suggesting a potential upside of 99.18%. Given BIOLASE's higher possible upside, research analysts plainly believe BIOLASE is more favorable than Altimmune.

Earnings & Valuation

This table compares BIOLASE and Altimmune's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BIOLASE$37.80 million3.50$-17,850,000.00($0.77)-1.18
Altimmune$5.80 million90.89$-20,520,000.00($0.98)-16.27

BIOLASE has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BIOLASE and Altimmune's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BIOLASE-58.34%-541.14%-45.22%
Altimmune-659.33%-46.39%-38.32%

Risk and Volatility

BIOLASE has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500. Comparatively, Altimmune has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500.

Insider & Institutional Ownership

5.5% of BIOLASE shares are owned by institutional investors. Comparatively, 66.2% of Altimmune shares are owned by institutional investors. 2.2% of BIOLASE shares are owned by insiders. Comparatively, 2.7% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

BIOLASE beats Altimmune on 7 of the 13 factors compared between the two stocks.

Amryt Pharma (NASDAQ:AMYT) and BIOLASE (NASDAQ:BIOL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk.

Profitability

This table compares Amryt Pharma and BIOLASE's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amryt PharmaN/AN/AN/A
BIOLASE-58.34%-541.14%-45.22%

Analyst Ratings

This is a breakdown of current ratings and price targets for Amryt Pharma and BIOLASE, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amryt Pharma01202.67
BIOLASE00103.00

Amryt Pharma currently has a consensus target price of $41.6667, indicating a potential upside of 182.68%. BIOLASE has a consensus target price of $2.00, indicating a potential upside of 120.46%. Given Amryt Pharma's higher probable upside, equities analysts clearly believe Amryt Pharma is more favorable than BIOLASE.

Insider and Institutional Ownership

15.4% of Amryt Pharma shares are held by institutional investors. Comparatively, 5.5% of BIOLASE shares are held by institutional investors. 2.2% of BIOLASE shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Amryt Pharma and BIOLASE's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amryt Pharma$58.12 million9.07$-30,753,600.00($0.86)-17.14
BIOLASE$37.80 million3.50$-17,850,000.00($0.77)-1.18

BIOLASE has lower revenue, but higher earnings than Amryt Pharma. Amryt Pharma is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Summary

Amryt Pharma beats BIOLASE on 8 of the 13 factors compared between the two stocks.

Biodesix (NASDAQ:BDSX) and BIOLASE (NASDAQ:BIOL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Institutional & Insider Ownership

5.5% of BIOLASE shares are held by institutional investors. 2.2% of BIOLASE shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Biodesix and BIOLASE, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biodesix00403.00
BIOLASE00103.00

Biodesix currently has a consensus target price of $24.3333, indicating a potential upside of 23.27%. BIOLASE has a consensus target price of $2.00, indicating a potential upside of 120.46%. Given BIOLASE's higher possible upside, analysts plainly believe BIOLASE is more favorable than Biodesix.

Valuation & Earnings

This table compares Biodesix and BIOLASE's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiodesixN/AN/AN/AN/AN/A
BIOLASE$37.80 million3.50$-17,850,000.00($0.77)-1.18

Biodesix has higher earnings, but lower revenue than BIOLASE.

Profitability

This table compares Biodesix and BIOLASE's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BiodesixN/AN/AN/A
BIOLASE-58.34%-541.14%-45.22%


BIOLASE Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
UROV
Urovant Sciences
0.7$16.17-0.1%$529.45 millionN/A-3.14
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.99-0.8%$529.03 million$143.01 million-1.14Earnings Announcement
Analyst Report
Analyst Revision
LABP
Landos Biopharma
1.3$13.48-3.6%$527.92 millionN/A0.00
ALT
Altimmune
1.9$15.94-7.9%$527.15 million$5.80 million-8.01Earnings Announcement
News Coverage
AMYT
Amryt Pharma
1.4$14.74-2.2%$527.10 million$58.12 million-17.14News Coverage
BDSX
Biodesix
1.4$19.74-2.7%$523.92 millionN/A0.00Gap Down
SeaSpine logo
SPNE
SeaSpine
1.3$18.92-3.0%$522.82 million$159.08 million-11.33Upcoming Earnings
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.7$36.70-1.9%$521.69 million$114.51 million-78.09Upcoming Earnings
News Coverage
OYST
Oyster Point Pharma
1.7$19.81-1.1%$513.28 millionN/A-5.71Analyst Downgrade
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$13.57-2.2%$512.46 million$4.36 million-4.74
LFMD
LifeMD
0.3$21.94-6.5%$508.59 millionN/A0.00Insider Buying
News Coverage
BeyondSpring logo
BYSI
BeyondSpring
1.2$12.98-0.6%$508.06 millionN/A-6.36
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$10.51-1.5%$507.69 millionN/A-5.39Upcoming Earnings
News Coverage
Gap Up
Global Cord Blood logo
CO
Global Cord Blood
0.9$4.16-7.2%$505.65 million$172.50 million7.05News Coverage
NLTX
Neoleukin Therapeutics
1.4$12.04-3.2%$504.90 million$25 million-18.52News Coverage
ZYXI
Zynex
1.7$14.52-20.0%$504.44 million$45.47 million44.00Earnings Announcement
Analyst Downgrade
High Trading Volume
News Coverage
Gap Up
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.6$15.29-1.6%$503.38 million$1.19 million-6.37
Affimed logo
AFMD
Affimed
1.6$5.67-5.3%$500.81 million$23.96 million-9.61News Coverage
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.43-5.0%$500.51 million$109.33 million-2.52
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.6$3.46-0.3%$500.11 million$335 million-1.17Earnings Announcement
News Coverage
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$6.74-2.1%$499.66 millionN/A-13.76Analyst Upgrade
Analyst Revision
AquaBounty Technologies logo
AQB
AquaBounty Technologies
1.4$7.09-1.3%$499.47 million$190,000.00-15.09
ANGN
Angion Biomedica
0.0$17.34-23.4%$498.02 millionN/A0.00
Spero Therapeutics logo
SPRO
Spero Therapeutics
1.5$18.17-1.2%$493.99 million$18.15 million-4.28
HARP
Harpoon Therapeutics
1.5$19.29-5.1%$489.58 million$5.78 million-9.06
SIGA
SIGA Technologies
0.3$6.32-0.9%$489.17 million$26.74 million15.80Upcoming Earnings
News Coverage
ETNB
89bio
1.6$24.56-1.3%$488.23 millionN/A-4.86
SNSE
Sensei Biotherapeutics
0.3$16.50-1.3%$487.71 millionN/A0.00Insider Buying
Gap Down
FUSN
Fusion Pharmaceuticals
1.5$11.68-2.7%$487.36 millionN/A0.00Upcoming Earnings
Analyst Downgrade
Gap Up
Homology Medicines logo
FIXX
Homology Medicines
1.7$10.74-0.9%$486.14 million$1.67 million-3.93High Trading Volume
SPRB
Spruce Biosciences
1.5$20.90-1.5%$485.17 millionN/A0.00Upcoming Earnings
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$7.97-0.5%$481.78 millionN/A-3.87Unusual Options Activity
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$12.26-4.6%$475.93 millionN/A-9.50
MIRM
Mirum Pharmaceuticals
1.9$18.36-2.0%$472.16 millionN/A-5.34Analyst Upgrade
Syros Pharmaceuticals logo
SYRS
Syros Pharmaceuticals
1.3$8.40-5.7%$472.06 million$1.98 million-5.06Upcoming Earnings
Analyst Upgrade
News Coverage
RCEL
AVITA Medical
1.4$21.74-7.1%$470.21 million$14.26 million-10.50News Coverage
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.04-5.2%$468.52 million$59.22 million40.20Unusual Options Activity
News Coverage
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$20.00-4.5%$467.46 millionN/A0.00Upcoming Earnings
Accuray logo
ARAY
Accuray
2.3$4.98-3.6%$462.63 million$382.93 million35.57
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$15.11-0.1%$462.28 millionN/A-4.35
Wave Life Sciences logo
WVE
Wave Life Sciences
1.8$9.41-0.0%$459.00 million$15.98 million-1.66Upcoming Earnings
Computer Programs and Systems logo
CPSI
Computer Programs and Systems
1.6$31.45-0.2%$456.40 million$274.63 million20.42
DBTX
Decibel Therapeutics
0.3$18.78-0.4%$456.39 millionN/A0.00Gap Up
Selecta Biosciences logo
SELB
Selecta Biosciences
1.6$4.22-1.4%$455.89 million$6.68 million-5.08
CLPT
ClearPoint Neuro
1.2$23.42-7.6%$455.87 million$11.22 million-53.23Upcoming Earnings
Analyst Revision
Gap Down
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.52-1.3%$455.64 million$49.65 million-2.14Upcoming Earnings
Quotient logo
QTNT
Quotient
1.6$4.49-0.9%$454.09 million$32.66 million-3.81Gap Down
DURECT logo
DRRX
DURECT
1.4$2.22-1.8%$451.06 million$29.56 million-44.39Upcoming Earnings
BIVI
BioVie
1.7$32.10-9.8%$446.70 millionN/A0.00
RAPT
RAPT Therapeutics
1.6$18.15-3.9%$445.67 millionN/A-7.15
This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.